for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurinia Pharmaceuticals Inc

AUPH.OQ

Latest Trade

12.80USD

Change

-0.16(-1.23%)

Volume

224,825

Today's Range

12.69

 - 

13.00

52 Week Range

12.01

 - 

20.50

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
12.96
Open
13.00
Volume
224,825
3M AVG Volume
3.88
Today's High
13.00
Today's Low
12.69
52 Week High
20.50
52 Week Low
12.01
Shares Out (MIL)
127.45
Market Cap (MIL)
2,066.22
Forward P/E
-12.99
Dividend (Yield %)
--

Next Event

Q1 2021 Aurinia Pharmaceuticals Inc Earnings Release

Latest Developments

More

Aurinia Pharmaceuticals Q4 Loss Per Share $0.05

FDA Approves Aurinia Pharmaceuticals’ Lupkynis (Voclosporin)

Aurinia And Lonza Announce Exclusive Agreement For Dedicated Voclosporin Manufacturing Capacity

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.

Industry

Biotechnology & Drugs

Contact Info

1203-4464 Markham St

VICTORIA, BC

V8Z 7X8

Canada

+1.250.7084272

https://www.auriniapharma.com

Executive Leadership

George M. Milne

Independent Chairman of the Board

Peter S. Greenleaf

President, Chief Executive Officer, Director

Dennis Bourgeault

Chief Financial Officer

Michael R. Martin

Chief Operating Officer

Stephen Robertson

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.1K

2021(E)

0.1K
EPS (USD)

2018

-0.760

2019

-1.330

2020

-0.870

2021(E)

-0.997
Price To Earnings (TTM)
--
Price To Sales (TTM)
32.82
Price To Book (MRQ)
4.01
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-27.49
Return on Equity (TTM)
-25.98

Latest News

Latest News

BRIEF-Aurinia Completes Patient Enrollment Into Audrey Phase 2/3 Clinical Trial Of Voclosporin Ophthalmic Solution

* AURINIA COMPLETES PATIENT ENROLLMENT INTO THE AUDREY PHASE 2/3 CLINICAL TRIAL OF VOCLOSPORIN OPHTHALMIC SOLUTION FOR THE TREATMENT OF DRY EYE SYNDROME

BRIEF-Aurinia Presents Additional Aurora Pivotal Trial Safety Data At The Era-Edta Virtual Congress 2020

* AURINIA PRESENTS ADDITIONAL AURORA PIVOTAL TRIAL SAFETY DATA AT THE ERA-EDTA VIRTUAL CONGRESS 2020 Source text for Eikon: Further company coverage:

BRIEF-Aurinia Presents Aurora Pivotal Trial Subgroup Analysis At Eular

* AURINIA PRESENTS AURORA PIVOTAL TRIAL SUBGROUP ANALYSIS AT THE EULAR 2020 E-CONGRESS Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharma Files For Mixed Shelf Of Up To Us $500 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO US $500 MILLION – SEC FILING Source text: (https://bit.ly/3euVkNi) Further company coverage:

BRIEF-Aurinia Completes Submission Of New Drug Application To U.S. FDA For Voclosporin For Treatment Of Lupus Nephritis

* AURINIA COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD & DRUG ADMINISTRATION FOR VOCLOSPORIN FOR TREATMENT OF LUPUS NEPHRITIS Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals Q1 Loss Per Share $0.15

* AURINIA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

BRIEF-Aurinia Appoints Joe Miller As Chief Financial Officer

* AURINIA PHARMACEUTICALS INC - DENNIS BOURGEAULT TO RETIRE AFTER MORE THAN 20 YEARS WITH COMPANY

BRIEF-Aurinia Announces Aurora Phase 3 Clinical Data For Voclosporin

* AURINIA ANNOUNCES AURORA PHASE 3 CLINICAL DATA FOR VOCLOSPORIN IN LUPUS NEPHRITIS TO BE PRESENTED AT NATIONAL KIDNEY FOUNDATION 2020 SPRING CLINICAL MEETINGS Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center In Rockville, Maryland

* AURINIA PHARMACEUTICALS ESTABLISHES U.S. COMMERCIAL OPERATIONS CENTER IN ROCKVILLE, MARYLAND Source text for Eikon: Further company coverage:

BRIEF-Aurinia Pharmaceuticals Initiates Rolling Submission Of A New Drug Application To The U.S. FDA For Voclosporin

* AURINIA PHARMACEUTICALS INITIATES ROLLING SUBMISSION OF A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR VOCLOSPORIN IN THE TREATMENT OF LUPUS NEPHRITIS

BRIEF-Aurinia Reports Qtrly Loss Per Share $0.78

* AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Aurinia Appoints Max Colao As Chief Commercial Officer And Expands U.S. Commercial Leadership Team

* AURINIA APPOINTS MAX COLAO AS CHIEF COMMERCIAL OFFICER AND EXPANDS U.S. COMMERCIAL LEADERSHIP TEAM Source text for Eikon: Further company coverage:

BRIEF-Aurinia Reports Qtrly Loss Per Share $0.18

* AURINIA REPORTS FIRST QUARTER FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up